Document is current
Any future updates will be listed below
-
Authors
Nehme, Jamil https://orcid.org/0000-0003-2771-2043
Maassen, Sjors
Bravaccini, Sara
Zanoni, Michele https://orcid.org/0000-0003-1826-9430
Gianni, Caterina
De Giorgi, Ugo
Soto-Gamez, Abel https://orcid.org/0000-0001-8975-1377
Altulea, Abdullah
Gheorghe, Teodora
Wang, Boshi https://orcid.org/0000-0002-9257-6714
Demaria, Marco https://orcid.org/0000-0002-8429-4813
-
Funding
Funding for this research was provided by:
KWF Kankerbestrijding (#14547)
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (09150172010029)
Hevolution Foundation (HF-GRO-23-1199094-17)
- License Information
-
More Information
Article History
Received: 4 July 2024
Revised: 9 January 2025
Accepted: 10 January 2025
First Online: 10 February 2025
Disclosure and competing interests statement
: M.D. is founder and shareholder of Cleara Biotech and advisor for Oisin Biotechnologies and Rubedo Life Sciences. The M.D. laboratory received funding from Ono Pharmaceuticals. None of the companies mentioned above were involved in this study. The remaining authors declare no competing interests.
